Inactive Instrument

Grifols SA Share Price BME

Equities

ES0171996012

Pharmaceuticals

End-of-day quote BME
- EUR - Intraday chart for Grifols SA
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 7.09B 7.7B 641B Sales 2025 * 7.58B 8.23B 686B Capitalization 5.98B 6.49B 541B
Net income 2024 * 416M 452M 37.63B Net income 2025 * 697M 757M 63.04B EV / Sales 2024 * 2.15 x
Net Debt 2024 * 9.25B 10.05B 837B Net Debt 2025 * 8.72B 9.47B 789B EV / Sales 2025 * 1.94 x
P/E ratio 2024 *
14.1 x
P/E ratio 2025 *
9.27 x
Employees -
Yield 2024 *
-
Yield 2025 *
2.35%
Free-Float 75.84%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 55 06/02
Director of Finance/CFO 67 01/07/01
Chairman 65 05/06/05
Members of the board TitleAgeSince
Chairman 65 05/06/05
Director/Board Member 68 13/00/13
Director/Board Member 61 27/01/27
More insiders
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW